Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  S. Rajkumar.  CME Information: Multiple Myeloma: 2014 update on diagnosis, risk-stratification and management , 2014 .

[3]  M. Boccadoro,et al.  The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status , 2014, Haematologica.

[4]  D. Ribatti,et al.  Microenvironment and multiple myeloma spread. , 2014, Thrombosis research.

[5]  M. Beksac,et al.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.

[6]  P. Selby,et al.  Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). , 2013, Blood reviews.

[7]  I. Borrello.  Can we change the disease biology of multiple myeloma? , 2012, Leukemia research.

[8]  A. Trumpp,et al.  Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.

[9]  G. Morgan,et al.  Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.

[10]  M. Pérez‐Andrés,et al.  CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features , 2011, Haematologica.

[11]  H. Johnsen,et al.  Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma , 2011, Leukemia.

[12]  Faisel Yunus,et al.  Statistics Using SPSS: An Integrative Approach, second edition , 2010 .

[13]  Shaji K. Kumar,et al.  Immunophenotyping in multiple myeloma and related plasma cell disorders. , 2010, Best practice & research. Clinical haematology.

[14]  J. Miguel,et al.  Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders , 2010, Cytometry. Part B, Clinical cytometry.

[15]  L. Kovarova,et al.  Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders , 2010, British journal of haematology.

[16]  C. Wallington-Beddoe,et al.  Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  D. Gómez-Almaguer,et al.  CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation , 2009, Transfusion.

[18]  B. Wood,et al.  Considerations for the control of background fluorescence in clinical flow cytometry , 2009, Cytometry. Part B, Clinical cytometry.

[19]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[20]  M. Terol,et al.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Bataille,et al.  CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. , 2008, Leukemia research.

[22]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[23]  Sharon L. Weinberg,et al.  Statistics Using IBM SPSS: An Integrative Approach , 2008 .

[24]  G. Morgan,et al.  A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma , 2007, Leukemia.

[25]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[26]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[28]  T. Therneau,et al.  Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.

[29]  Wendy N. Erber,et al.  Blood and Bone Marrow Pathology , 2002 .

[30]  R. Johnson,et al.  Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve , 2001, British journal of haematology.

[31]  G. Morgan,et al.  B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors , 1998, British journal of haematology.

[32]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[33]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.